We are focused on establishing strategic partnerships to accelerate the growth and development of impactful tissue therapies. We collaborate with pharmaceutical and biotechnology companies as well as academic researchers to develop biologically and commercially impactful human tissues. Our microfluidic 3D bioprinting technology provides unprecedented flexibility and control over 3D heterogeneous tissue fabrication. By combining our capabilities and platform technology with domain expertise, we are able to unlock the full potential of bioprinting technology. Please contact us to explore partnering opportunities.
Tearing your meniscus, the “shock absorber” of your knee, is one of the most common knee injuries, and incidence is expected to rise with an aging population. Surgical treatment of a torn meniscus may involve partial or complete removal, which is associated with increased occurrence of osteoarthritis.
Using our microfluidic 3D bioprinting technology, we partnered with DePuy Synthes Products Inc., a Johnson and Johnson company, to develop bioprinted knee meniscus tissue with the potential for surgical implantation.
When a new drug is developed and brought to clinical trial, it often faces the problem of unforeseen liver toxicity. By developing a predictive and human-relevant liver tissue platform in collaboration with JSR, we aim to tackle this problem, enable the modeling of diseases, and accelerate the development of new medicines.PRESS RELEASE
Our 3DBioRing™ Airway tissue is the world's first 3D printed airway tissue that exhibits highly physiological contraction and relaxation responses in vitro. Treatment with histamine triggers an asthma attack-like concentration-dependent contraction, with exposure to salbutamol causing rapid, pharmacologically-relevant relaxation. We are collaborating with a top 10 global pharmaceutical company to investigate their novel compounds in our human-relevant bioprinted airway tissue.
Dr. Lorenzo Moroni and Dr. Carlos Mota at Maastricht University are 3D bioprinting kidney tissue for pre-clinical and regenerative medicine applications. This includes developing solutions for tissue and organ replacement, as well as in vitro kidney models to predict nephrotoxicity and study disease in the biopharmaceutical industry.
Dr. Stephanie Willerth at the University of Victoria is developing neural tissues derived from human induced pluripotent stem cells (hiPSCs). These tissues can be used for disease modeling, as a tool for screening neural disease drug targets such as Alzheimer's disease, and for regenerative medicine applications such as treating spinal cord injury (SCI).
In lung diseases such as asthma or pulmonary fibrosis, there are changes in the mechanical properties of the organ, including both stiffening and softening of the tissue. Dr. Adrian West at the University of Manitoba is using our microfluidic 3D bioprinting technology and contractile airway tissue platform to study these changes and test novel therapeutic strategies to treat lung diseases.
We have partnered with Dr. Iain Buxton at the University of Nevada to develop a uterine smooth muscle model based on our 3DBioRing™ contractile tissue platform. In the long term, results from this work may identify potential molecular targets for regulating uterine contractility to halt preterm labour.